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ABSTRACT Flexible linkers are often found to tether binding sequence motifs or connect protein domains. Here we analyze
three usages of ﬂexible linkers: 1), intramolecular binding of proline-rich peptides (PRPs) to SH3 domains for kinase regulation;
2), intramolecular binding of PRP for increasing the folding stability of SH3 domains; and 3), covalent linking of PRPs and other
ligands for high-afﬁnity bivalent binding. The basis of these analyses is a quantitative relation between intermolecular and
intramolecular binding constants. This relation has the form Ki ¼ Ke0p for intramolecular binding and Ke ¼ Ke01Ke02p for bivalent
binding. The effective concentration p depends on the length of the linker and the distance between the linker attachment points
in the bound state. Several applications illustrate the usefulness of the quantitative relation. These include intramolecular
binding to the Itk SH3 domain by an internal PRP and to a circular permutant of the a-spectrin SH3 domain by a designed PRP,
and bivalent binding to the two SH3 domains of Grb2 by two linked PRPs. These and other examples suggest that ﬂexible
linkers and sequence motifs tethered to them, like folded protein domains, are also subject to tight control during evolution.
INTRODUCTION
Unstructured regions of proteins increasingly are found to
play regulatory and signaling roles (1,2). One mode of action
is through the binding of a peptide motif within an unstruc-
tured region to a target protein domain. Many such peptide
motifs have been identiﬁed (3). Prominent among these is a
proline-rich peptide (PRP) that binds to SH3 domains. X-ray
structures of Src, Hck, and Abl kinases (4–8) show that
intramolecular binding to the SH3 domain by a PRP within
the linker between the SH2 and kinase domains provides an
important mechanism for suppression of kinase activity
(Fig. 1 a). These structures also immediately suggest a mech-
anism for kinase activation through intermolecular PRP-
binding to the SH3 domain, leading to the release of the SH3
domain from the intramolecular PRP (Fig. 1 b). Previously
we have developed a quantitative relation between intermo-
lecular and intramolecular binding and applied the relation to
examine the effects of covalent linking in protein folding
stability (9) and in protein-DNA and antibody-antigen bind-
ing afﬁnity (10,11) as well as the role of intramolecular bind-
ing of the myristoylated N-terminal in Abl kinase regulation
(12). In this article we apply the relation to rationalize a num-
ber of recent experimental results on intramolecular PRP-
SH3 binding in kinase regulation and on enhancement of
folding stability and binding afﬁnity through covalent link-
ing of PRP ligands.
One type of intramolecular binding studied here is
between a PRP connected to an SH3 domain via a ﬂexible
linker (Fig. 1 c). In particular, this models the arrangement of
PRP and SH3 domains in the Tec family of nonreceptor
tyrosine kinases (13–17) and in the diphtheria toxin repressor
(18). The quantitative relation between intermolecular and in-
tramolecular binding suggests that, while there is evolution-
ary pressure to increase the binding afﬁnity of SH3 domains
for external PRP from target proteins, it may be advanta-
geous to maintain the afﬁnity for internal PRP at a relatively
low level. Hence in Src, Hck, and Abl kinases the sequences
of internal PRP deviate signiﬁcantly from those of high-af-
ﬁnity ligands (19,20). Similarly, a PRP within Btk, a member
in the Tec family of kinases, was found to bind with the SH3
domains of Fyn, Hck, and Lyn kinases, but not with Btk’s
own SH3 domain (21). Indeed, the binding constants of Tec
family kinases for their internal PRPs are typically found to
be of the order of 103 M1 (15–17). In contrast, the afﬁnity
of SH3 domains for PRPs on target proteins can reach
106 M1 or higher (22–26).
The binding site for PRP is formed only when the SH3 is
folded. Therefore in a folding transition PRP-binding can
shift the equilibrium from the unfolded to folded state. The
presence of an intramolecularly bound PRP is thus expected
to increase the folding stability of the SH3 domain. Such
stabilization has been observed in SH3 domains with de-
signed intramolecular PRPs (27,28). The quantitative relation
between intermolecular and intramolecular binding allows
for calculation of the effect of the intramolecular PRPs on the
unfolding free energy.
When a protein has multiple binding sites, a high-afﬁnity
ligand can be obtained by covalently linking peptide motifs
that target the individual binding sites. Such bivalent ligands
have been designed to simultaneously bind to the SH3 and
SH2 domains of Abl kinase (29,30), the SH2 and kinase
domains of Src kinase (31,32), and the two SH3 domains
of Grb2 (33–35). In each of these cases there is strong ex-
perimental evidence indicating rearrangement between the
domains upon ligand binding (6,32,34,36). Previously the
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afﬁnity-enhancement role of covalent linking has been ana-
lyzed for one of these ligands without considering the effect of
domain rearrangement (11). Here this effect is incorporated to
analyze the afﬁnity of bivalent ligands. The analysis helps
dispel misconception regarding bivalent binding that has
appeared in the literature and provides an indication on the
range of afﬁnity enhancement expected from bivalent binding.
THEORY
Binding of PRP to SH3 domain, with and without
ﬂexible linker
When a PRP is attached to an SH3 domain by a ﬂexible linker, the intra-
molecular binding constant Ki can be related to the intermolecular binding
constant Ke0, observed when the linker is cleaved (Fig. 2 a). Under the
assumption that the PRP and the SH3 domain do not interfere with the
statistical distribution of the linker, except that the binding restrains the end-
to-end distance of the linker to a distance d, it was shown (10,37)
Ki ¼ Ke0pðdÞ; (1)
where p(d) is the probability density for the end-to-end vector of the linker at
the distance d. The value p(d) plays the role of effective concentration. It has
been found that peptide linkers can be modeled well as wormlike chains
(38). For a linker consisting of L peptide bonds, an approximate expression
for p(d) is then
where lc and lp are the contour length and persistence length, respectively, of
the peptide linker. The contour length can be calculated as bL, where
b¼ 3.8 A˚ is the nearest Ca-Ca distance. The persistence length was found to
be ;3 A˚ for peptide linkers.
Cross-binding and dimerization
An SH3 domain can bind with not only its internal PRP but also the PRP on
another molecule. Let us consider the general case of cross-binding between
two different types of PRP-SH3 molecules. As illustrated in Fig. 2 b, there
are a total of seven distinct monomeric and dimeric species: bound and un-
bound molecule 1 (denoted asMb1 andMu1), bound and unbound molecule 2
(denoted asMb2 andMu2), two types of singly bound dimers (denoted as Dbu
and Dub), and doubly bound dimer (denoted as Dbb). Higher oligomers can
also form, but is not considered here. With the binding constants shown in
Fig. 2 b, the concentrations of the seven species are related by
½Mb1 ¼ Ki1½Mu1 (3a)
½Mb2 ¼ Ki2½Mu2 (3b)
½Dbu ¼ Ke1½Mb1½Mb2 (3c)
½Dub ¼ Ke2½Mb1½Mb2 (3d)
½Dbb ¼ K9i2½Dbu ¼ K9i1½Dub: (3e)
Note that Eqs. 3c–e require
Ke1K9i2 ¼ Ke2K9i1: (4)
When the two types of PRP-SH3 molecules are present at the same total
concentration Ct, one ﬁnds
ð11Ki1Þ½Mu1 ¼ ð11Ki2Þ½Mu2 (5a)
¼ 11 ð11 8KaCtÞ
1=2
4KdCt
Ct[ f ðKaCtÞCt; (5b)





The apparent dimerization constant in the present situation is given by
Ka ¼ ðKe11Ke21Ke1K9i2Þ=2ð11Ki1Þð11Ki2Þ: (6)
Suppose that the binding equilibria are monitored by a signal-like chemical
shift. For the simple monomer-dimer equilibrium, if the signals of pure
monomer and pure dimer are sm and sd, then the signal at a total monomer
concentration of Ct is
s ¼ smf ðKaCtÞ1 sd½1 f ðKaCtÞ ¼ ðsm  sdÞf ðKaCtÞ1 sd:
(7)
Let us assume that, for each type of SH3 domain, the bound species all give the
same signal sba (a¼ 1 or 2) and the unbound species all give the same signal
sua. At equilibrium the actual signals from the two types of molecules are
s1 ¼ su1ð½Mu11 ½DubÞ=Ct1 sb1ð½Mb11 ½Dbu1 ½DbbÞ=Ct;
(8a)
s2 ¼ su2ð½Mu21 ½DbuÞ=Ct1 sb2ð½Mb21 ½Dub1 ½DbbÞ=Ct:
(8b)
These can be expressed in the same form as Eq. 7, with the apparent
monomer and dimer signals given by
sma ¼ sba1 sua  sbað11KiaÞ; (9a)
FIGURE 1 PRP-binding to SH3 domains in kinase regulation. (a) Sup-
pression of kinase activity through intramolecular binding to the SH3 do-
main by a PRP in the SH2-kinase linker of a Src-like kinase. (b) Kinase
activation through intermolecular PRP binding to the SH3 domain. This
binding leads to the release of the internal ligand and activation of the kinase.
The external PRP may reside in a regulatory protein; upon kinase activation
a separate substrate will subsequently bind to the kinase domain. Alterna-
tively, the external PRP may be part of a substrate protein. Binding of the
PRP then also serves to anchor the substrate on the kinase. (c) Intramolecular
binding and unbinding of a PRP to an SH3 domain. The PRP is connected to
the SH3 domain by a ﬂexible linker.
p0ðd; LÞ ¼ ð3=4plplcÞ3=2expð3d2=4lplcÞð1 5lp=4lc1 2d2=l2c  33d4=80lpl3c  79l2p=160l2c
 329d2lp=120l3c 1 6799d4=1600l4c  3441d6=2800lpl5c 1 1089d8=12800l2pl6cÞ; (2)
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sda ¼ sba1 ðsua  sbaÞKe1Ke2
KeaðKe11Ke21Ke1K9i2Þ; (9b)
for a ¼ 1 or 2.
The cross-binding model of Fig. 2 b has six binding constants. To gain
further insight on these binding constants, let us consider a control
experiment in which the linkers on the two types of PRP-SH3 molecules are
cleaved and bimolecular binding of the two types of PRP to each of the two
types of SH3 domains is then observed. Let the binding constants of SH3
domain a for the internal and external PRP be Kea0 and Ke9a0, respectively.
The cross-binding constant Kea can be approximated by Ke9a0. The
intramolecular binding constant Kia can be related to Kea0 through Eq. 1,
Kia ¼ Kea0p0ðda; LaÞ: (10a)
Here, da is the distance between the attachment point of the linker and the
PRP binding site on SH3 domain a, and La is the linker length. An
analogous relation between the intramolecular binding constant K9i1, for
forming Dbb from Dub, and Ke10 can be proposed,
K9i1 ¼ Ke10p1ðd1; L1; d2; L2Þ; (10b)
where p1(d1;L1,d2,L2) is the probability density for the end-to-end vector of a
composite linker, consisting of the ﬂexible peptide (with length L1) attached
to the ﬁrst SH3 domain, a rigid connector with length d2, and the ﬂexible
peptide (with length L2) attached to the second SH3 domain. Similarly,
K9i2 ¼ Ke20p1ðd2; L2; d1; L1Þ: (10c)
Since the two SH3 domains will have excluded-volume interactions and
perhaps even speciﬁc interactions, the last two relations may not be very
accurate. It can be shown that p1(d1;L1,d2,L2) ¼ p1(d2;L2,d1,L1), conse-
quently the last two relations are consistent with the requirement of Eq. 4,
Ke1K9i2 ¼ Ke2K9i1.
A PRP-SH3 molecule can always cross-bind with another molecule of
the same type. The homodimerization process involves four distinct species:
bound and unbound monomer (denoted as Mb and Mu), singly-bound dimer
(denoted as Ds), and doubly-bound dimer (denoted as Dd). Since occupation
of the PRP binding site on either Mu molecule leads to Ds, the binding
constant for forming Ds from two Mu molecules is 2Ke, where Ke  Ke0 is
the binding constant if only one of the two identical binding sites were
available. By the same token, release of either PRP from Dd leads to Ds,
hence the binding constant for forming Dd from Ds is K9i/2, where K9i 
Ke0p1(d;L,d,L) is the binding constant if only one of the two identical PRP on
Dd were allowed to release. With these considerations, the results derived
earlier for heterodimerization can be easily adapted for the present
homodimerization process. The apparent dimerization constant is
Ka ¼ ð2Ke1KeK9iÞ=ð11KiÞ2: (11)
The signals at zero and inﬁnite protein concentration are
sm ¼ sb1 su  sb
11Ki
; sd ¼ sb1 ðsu  sbÞ
21K9i
: (12)
Folding of PRP-SH3 molecule
To understand the equilibrium of a PRP-SH3molecule between the unfolded
and folded states, it is convenient to introduce an intermediate (either
ﬁctitious or real), in which the SH3 is folded by itself but the PRP is not
bound (Fig. 2 c). If the folding equilibrium constant for the SH3 domain
alone is Kf0 and the intramolecular PRP binding constant is Ki, then the
overall folding equilibrium constant is
FIGURE 2 Models of intermolecular and intramo-
lecular PRP-SH3 binding. (a) PRP-SH3 binding in the
absence and presence of a ﬂexible linker. (b) Binding
of an SH3 domain with its internal PRP or with a PRP
attached to another SH3 domain. The latter leads to
dimerization of the two SH3 domains. (c) Intramolec-
ular binding preceded by a folding transition of the
SH3 domain. (d) Binding of a bivalent ligand to two
sites on the same target or on two targets connected by
a ﬂexible linker.
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Kf ¼ Kf0Ki: (13)
Kf0 can be mimicked by the folding equilibrium constant of the SH3 with the
PRP cleaved. The effect of the PRP on the unfolding free energy is thus
DDGu ¼ kBT lnKf  kBT lnKf0 ¼ kBT lnKi: (14a)
Ki can be obtained, by Eq. 1, from the intermolecular binding constant Ke0 of
the SH3 domain for the cleaved PRP. Hence,
DDGu ¼ kBT ln ½Ke0pðdÞ: (14b)
Since the SH3 domain autonomously folds and the PRP binding site is
presented only after the SH3 domain is folded, it is reasonable to consider
the intermediate as real and on-pathway. It can be further suggested that the
transition state for the SH3 domain is also the transition state for the PRP-
SH3 molecule. Then the overall folding and unfolding rate constants are
related to those of the SH3 domain by
kf ¼ kf0; (15a)
ku ¼ ku0=Ki: (15b)
That is, the PRP only affects the unfolding rate.
Binding of bivalent ligand
Consider two ligands that bind to separate binding sites on the same target
protein with binding constants Ke01 and Ke02. If the two ligands are con-
nected by a linker (Fig. 2 d), then the bivalent ligand will have afﬁnity
Ke ¼ Ke1Ki2 ¼ Ke2Ki1: (16a)
With Ke1  Ke10 and Eq. 1 for Ki2, one arrives at the result derived
previously (10,11),
Ke ¼ Ke10Ke20pðdÞ; (16b)
where p(d) is the probability density for the end-to-end vector of the linker at
the distance d separating the two binding sites.
When the two binding sites are located on two domains connected by a
ﬂexible linker (Fig. 2 d), the binding constant between the linked domains
and the bivalent ligand is
Ke ¼ Ke1Ki92 ¼ Ke2Ki91: (17a)
With Ke2  Ke20 and Eq. 10c for K9i1, one arrives at
Ke ¼ Ke10Ke20p1ðd1; L1; d2; L2Þ; (17b)
where L1 and L2 are the lengths of the linkers connecting the two target
domains and the two ligands, da is the distance between the attachment point
of the interdomain linker and the ligand-binding site on domain a, and the
meaning of the probability density p1(d1;L1,d2, L2) has been given after Eq.
10b. This formulation can be further extended when the two domains are not
connected directly by a single ﬂexible linker but by linkers from both sides
to yet a third domain, like the situation between the two SH3 domains in
Grb2.
Calculation of probability density
In previous studies of the relation between intermolecular and intramolecular
binding (9–12), the probability density p(d) was estimated by Eq. 2. In
addition, the peptide linker was allowed to start in any direction off the
attachment point on a protein domain or a ligand. To improve on both
aspects, here we used conformation sampling of the peptide linker to
calculate p(d).
The wormlike chain modeling a peptide linker was represented as a freely
rotating chain with a bond-length approaching zero and a bond-angle
approaching 180 (39). In our implementation, each chain was represented
by J ¼ 1000 bonds, with a bond-length s ¼ lc/J and a bond-angle of u ¼
acos(s/lp – 1). The Ca-Ca vectors immediately before and immediately after
the peptide linker were used to enforce directionality of the start bond (i.e.,
bond 1) and end bond (i.e., bond J) of the linker. For concreteness, suppose
that sequentially the SH3 domain is followed by the linker and then by the
PRP. Let the residue number of the last SH3 residue be ns and the residue
number of the ﬁrst PRP residue be ne. The Ca-Ca vector vs from residue ns
1 to residue ns constrains the direction of bond 1 of the linker, and the Ca-Ca
vector ve from residue ne to residue ne1 1 constrains the direction of bond J
of the linker. In the unbound state, vs and ve would have arbitrary relative
orientations, but in the bound state the relative orientation of vs and ve is
ﬁxed. In addition, the end-to-end vector of the linker, identical to the Ca-Ca
vector d from residue ns to residue ne, is also ﬁxed relative to vs and ve. To
emphasize that the directionality of the start and end bonds of the linker is
constrained, the probability density of the end-to-end vector is now denoted
as p(d).
The enforcement of directionality for the start and end bonds and the
calculation of p(d) were implemented as follows. A wormlike chain was
started at the origin with bond 1 at an arbitrary direction. After growing the
chain to bond J, the end-to-end vector of the chain was lined up with d. Upon
this lineup, if the angle between bond 1 and vector vs and the angle between
bond J and vector ve were both less than a constraint angle gc, then the chain
conformation was accepted. For each calculation of p(d), a total of Nconf ¼
107 chain conformations were started. Of these, the number of chains with
start and end bonds satisfying directionality constraints and with end-to-end
distances falling between d – D/2 and d1 D/2 was obtained. Let this be n(d).
The probability density p(d) was found as n(d)/4pd2D[(1 – cosgc)/2]
2Nconf.
The bin size D was 102lc.
The corresponding probability density for a composite linker, with
directionally constrained start and end bonds for the ﬂexible components, is
now denoted as p1(d1;L1,d2,L2). The composite linker consists of a ﬂexible
chain with length L1, a rigid connector spanned by vector d2, and another
ﬂexible chain with length L2. In the bound state, the two ﬂexible chains link
up two domains. The directions of the start bond of chain 1 and the end bond
of chain 2 are constrained by vectors vs1 and ve1, respectively, which are
ﬁxed in the ﬁrst domain. Similarly, the directions of the end bond of chain
1 and the start bond of chain 2 are constrained by vectors ve2 and vs2,
respectively, which are ﬁxed in the second domain.
The procedure for obtaining p1(d1;L1,d2,L2) was the same as that for p(d),
with vector d2 treated as a special bond. Each ﬂexible chain was represented
by J ¼ 1000 bonds. After the Jth bond of chain 1, vector ve2 was randomly
distributed within a cone that spans an angle gc around bond J. Vector d2
was then randomly distributed around vector ve2, keeping the angle between
them as found in the second domain. The directions of ve2 and d2 allowed for
unique positioning of vs2. Finally chain 2 was started off randomly within a
cone that spans an angle gc around vs2. This procedure was extended to Grb2
by an additional ﬂexible linker followed by a rigid domain.
A value of 90 was assigned to the constraint angle gc. The persistence
length of any ﬂexible chain connected to a PRP ligand was 3 A˚. For linkers
between two protein domains, the value of lp was 10 times higher.
RESULTS
Intermolecular and intramolecular PRP binding of
Itk, Rlk, and Btk SH3 domains
Andreotti et al. (13) found that the SH3 domain of Itk forms
an intramolecular complex with the K3KPLPPTP10 sequence
located at the N-terminal (Fig. 3 a). Here numerical
superscripts are used to denote residue numbers as found
in PDB entry No. 1awj. The N-terminal of the SH3 domain is
Inter- and Intramolecular Binding 3173
Biophysical Journal 91(9) 3170–3181
found on the opposite side of the PRP binding site. The
linker has to make a sharp turn to tether the PRP. Laederach
et al. (17) measured the binding constant Ke0 of the cleaved
PRP sequence, KNASKKPLPPTP, with the SH3 domain
and found Ke0 ¼ (0.17 6 0.02) 3 103 M1.
To apply Eq. 1 to predict the intramolecular binding
constant Ki, the two ends of the ﬂexible linker have to be
speciﬁed. It seems reasonable to deﬁne the linker as the
sequence, E11DNRRSFQEPEET23, between the PRP and the
sharp turn at the N-terminal of the SH3 domain. This linker
sequence is shown as black ball-and-stick in Fig. 3 a. The
end-to-end distance d, measured between the Ca atoms of
residues P10 and L24, is 22.5 A˚. With L ¼ 14 peptide bonds,
the effective concentration p(d) was found by conforma-
tional sampling to be 13.5 mM. Equation 1 then predicts Ki¼
0.17 3 103 M1 3 13.5 mM ¼ 2.3. This is to be compared
with the experimental value of 0.54 6 0.1 obtained by
Laederach et al. (17).
Laederach et al. (17) also studied the effect of deleting ﬁve
residues, S16FQEP20, of the linker sequence. With L re-
ducing from 14 to 9, we ﬁnd p(d) lowering to 3 mM and
predict Ki ¼ 0.5. This is to be compared with the ex-
perimental value of 0.11 6 0.05. The much lower value of
p(d) arises from the low probability for the end-to-end vector
of the shortened linker to span a large distance of 22.5 A˚.
Laederach et al. (17) did not ﬁnd evidence for Itk PRP-
SH3 dimerization at protein concentrations up to 1 mM.
Equation 11 gives the apparent dimerization constant Ka.
Neglecting the unknown K9i, we ﬁnd Ka  2Ke0/(1 1 Ki)2 ¼
0.14 3 103 M1. At Ct ¼ 1 mM, the monomer fraction is
expected to be 81% Eq. 5b. Apparently, weak intermolecular
binding and relatively strong intramolecular binding work
together to keep dimerization at a low level for Itk PRP-SH3.
Laederach et al. (17) also studied the binding of PRP
sequence QPSKRKPLPPLP in the Rlk SH3 domain. The
bimolecular binding constant of this PRP was (1.2 6 0.1) 3
103 M1. The intramolecularly bound fraction (i.e., Ki/(1 1
Ki)) of the PRP was very low, at 0.07 6 0.1. The corre-
sponding Ki value is 0.075. Without a structure of the intra-
molecular complex, it is not possible to quantitatively explain
the small Ki value. However, Laederach et al. (17) found the
intramolecularly bound fraction of the QPSKRKPLPPLP
sequence increasing to 0.25 6 0.05 (Ki ¼ 0.33) when ﬁve
residues were inserted in the linker sequence; this increase
FIGURE 3 Intramolecular PRP-SH3 com-
plexes. SH3 domains are shown as brown ribbon,
PRP as blue ball-and-stick, linkers between them
as black ball-and-stick, and SH3 residues in con-
tact with PRP as red ball-and-stick. (a) Itk SH3
bound with an N-terminal PRP (PDB No. 1awj).
Sequence alignment of the N-terminal portions of
Itk, Rlk, and Btk are also shown. (b) S19P20s
bound with P41 (PDB Nos. 1tuc and 1bbz). (c)
Hck SH3 bound with GAP PRP (PDB No. 5hck).
1wa7 SH3 is shown as cyan trace; 1qcf is in
green (SH3 as trace, SH2 as ribbon, PRP in SH2-
kinase linker as ball-and-stick).
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can be qualitatively explained by the expected increase in
p(d). From sequence alignment between Rlk and Itk over the
PRP and SH3 regions (Fig. 3 a), the native linker sequence of
Rlk may be identiﬁed as QEPPDERI. The insertion of ﬁve
residues within this sequence increases the linker length from
9 to 14.
In a separate article, Laederach et al. (16) studied PRP
binding of the Btk SH3 domain. This SH3 domain is pre-
ceded by two PRP sequences (KKPLPPTP and KKPLPPEP;
Fig. 3 a). Only the ﬁrst PRP, separated from the SH3 domain
by a longer sequence, was found to be capable of intramo-
lecular binding, even though both PRPs were found to be
capable of cross-binding to a different SH3 domain. The in-
crease in Ki, from not measurable for the second PRP to 0.29
for the ﬁrst PRP, with the increase in linker length, is similar
to the situations with Itk and Rlk kinases. The bimolecular
binding constant Ke0 can be obtained as half of the apparent
dimerization constant of the Pr*PrSH3 mutant, which is
incapable of intramolecular binding within either the mon-
omer or the dimer (i.e., Ki ¼ K9i ¼ 0), resulting in Ke0 ¼ 0.4
3 103 M1. On the other hand, Patel et al. (40) reported a
binding constant of 183 103 M1 for the peptide, TKKPLP-
PTPE, corresponding to the ﬁrst PRP. The reason for the
nearly 50-fold difference in Ke0 is not clear; possibly the at-
tached SH3 domain interferes with the cross-binding of the
PRP to a separate SH3 domain.
In all the Tec family kinases, the bimolecular binding
constant Ke0 is found to be of the order of 10
3 M1. Since
typical values of p(d) are of the order of 1 mM, the resulting
value of Ki will be ;1. Such a Ki will ensure that the PRP
binding site is unoccupied by the internal ligand for a sub-
stantial fraction of time, thereby allowing for the displace-
ment of the internal ligand by an external ligand. The 103 M1
order of magnitude for Ke0 values of the Tec family kinases
thus seems important for regulatory purposes.
Effects of intramolecular PRP binding on folding
of S19P20s and HcK SH3 domains
Matrin-Sierra et al. (28) linked the P41 PRP sequence
A1PSYSPPPPP10 to the C-terminal of the circular permutant
S19P20s of the a-spectrin SH3 domain and studied the effect
on folding stability. The bimolecular binding constant of the
PRP to S19P20s was Ke0 ¼ 6.3 3 103 M1.
The structure of the P41-S19P20s complex can be
modeled after the complex of P41 with the Abl SH3 domain
(PDB entry No. 1bbz) (41). The six P41-contacting residues
(Y7, F9, W36, W47, P49, and Y52) in 1bbz can be super-
imposed to the corresponding residues (Y13, Y15, W41, F52,
P54, and Y57) in S19P20s (PDB entry No. 1tuc) (42) with a
backbone RMSD of only 0.2 A˚. With this superposition, the
C-terminal of S19P20s (E17 Ca) and the N-terminal of the
P41 N-terminal (A1 Ca) is 12.9 A˚ (Fig. 3 b). These two
residues were connected by the linker sequence SGDN,
resulting in a linker length of ﬁve peptide bonds. For the
above d and L, p(d) is 65 mM. Equation 14b then predicts
stabilization of DDGu¼ 14.9 kJ/mol by the covalently linked
P41. This prediction is comparable with the experimental
result of 8.3 kJ/mol.
Gmeiner et al. (27) appended the PRP sequence G131GGF-
PPLPPPPYLPPLGAGL150 of human Ras GTPase-activating
protein (GAP) to the Hck SH3 domain and studied the effect
on unfolding rate by mass spectroscopy after H/D exchange.
The particular SH3 construct contains part of the SH3-SH2
linker of Hck, ending with the sequence V136DSLETEE143,
but the last ﬁve residues appear unstructured (PDB entry No.
5hck) (43). There is also a two-residue (AG) insertion be-
tween the SH3 construct and the GAP PRP. The bimolecular
binding constant Ke0 of the GAP PRP for the Hck SH3 do-
main was measured to be (2–10) 3 104 M1 (43).
We searched the PDB for a template to build a homology
model for the Hck SH3-GAP PRP complex and found entry
No. 1wa7 for the purpose. This is the complex between the
Fyn SH3 domain and the tyrosine-kinase interacting protein
(Tip) PRP W170DPGMPTPPLPPRPANLGERQA191 (44).
There are only two substitutions between the proline-rich
segments T176PPLPPRP183 of Tip and F134PPLPPPP141 of
GAP. The backbone RMSD of the two SH3 domains is 1.2 A˚
after superimposing residues V84 to A134 of 5hck with res-
idues V14 to A64 of 1wa7 (Fig. 3 c). This RMSD is very close
to the value of 1.0 A˚ obtained between the structures of the
Hck SH3 domain in isolation and in intact Hck kinase (PDB
entry No. 1qcf) (7). The Tip PRP sequence G173MPTPP-
LPPRPAN185 has a similar binding constant, 8.33 104 M1
(44), as the GAP PRP for the Hck SH3 domain.
We take residue V136 of the Hck SH3 domain to be the at-
tachment point of the linker to the GAP PRP. After this res-
idue, conformations start to diverge among 5hck, 1wa7, and
1qcf. At the other end, the attachment point of the linker is
taken to be G133 of the GAP PRP. This residue aligns with
P175 of the Tip PRP. The resulting linker sequence is DSL-
ETEEAGGG, with length L ¼ 12 peptide bonds. The linker
end-to-end distance in the bound structure is then measured
from V136 of 5hck and P175 of the Tip PRP in 1wa7 after
superposition of the SH3 domains. The result is d ¼ 21.3 A˚.
For these values of L and d, we ﬁnd p(d) ¼ 13.7 mM. The
folding equilibrium constant is then increased by a factor of
Ki ¼ Ke0p(d) ¼ 270–1370 upon covalently linking the GAP
PRP for intramolecular binding. If we assume that the fold-
ing rate is unaffected by the covalent linking, then the un-
folding rate should be reduced by the above factor. By mass
spectroscopy Gmeiner et al. (27) found a factor of ;40 for
the slowing down of unfolding. It is possible that the exper-
imental value for the decrease in unfolding was underes-
timated, as mass spectroscopy after H/D exchange might
actually probe local instead of global unfolding.
Fig. 3 c shows that the internal PRP of Hck kinase is not as
closely packed against the SH3 domain as the Tip PRP is.
The internal PRP has the sequence K249PQKPWE256 and the
two lysine residues appear to be responsible for the loose
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packing. Lerner et al. (20) found that mutating them into
prolines signiﬁcantly increases the intramolecular binding
afﬁnity.
Bivalent binding to Abl SH3-SH2, Src SH2-Kinase,
and Grb2 SH3-SH3 domains
Xu et al. (30) constructed a bivalent ligand for the Abl SH3-
SH2 domains (SH(32)) by connecting the C-terminal of SH3
ligand 3BP-2 (P1PAYPPPPVP10) and the N-terminal of SH2
ligand 2BP-1 (P1V(Yp)ENV
6; Yp denotes phosphorylated
tyrosine). Separately, the individual ligands have binding
constants of Kea0 ¼ 9.5 3 104 and 5.0 3 105 M1 (29), for
the SH3 and SH2 domains. By connecting P10 of 3BP-2 and
P1 of 2BP-1 by an eight-residue linker, Xu et al. (30) found
Ke ¼ 5.3 3 106 M1 for the bivalent ligand. Fushman et al.
(36) observed substantial changes in the overall spatial ar-
rangement of the two domains upon binding a bivalent li-
gand. It is thus not appropriate to predict Ke by Eq. 16b,
which would treat Abl SH(32) as rigid.
To use Eq. 17b to predict Ke, we need the distances
between P10 of 3BP-2 and the attachment point of the SH3-
SH2 linker on the SH3 domain and between P1 of 2BP-1 and
the attachment point of the SH3-SH2 linker on the SH2
domain. We take the two attachment points to be P137 and
W146 (residue numbering according to PDB entry No. 2abl;
Fig. 4 a) (45). The distances can be measured in the complex
of the Abl SH3 domain and a 3BP-2 homolog (A1PTM-
PPPLPP10) (PDB entry No. 1abo) (46) and the complex of
Grb2 SH2 and a 2BP-1 homolog [K-1P1F(Yp)VNV
6EF]
(PDB entry No. 1bmb) (47). The results are d1 ¼ 18.9 A˚ and
d2¼ 21.3 A˚. The linker lengths are L1¼ L2¼ 9. The value of
p1(d1;L1,d2, L2) is then 2.1 mM, leading to a prediction of
Ke ¼ Ke10Ke20p1(d1;L1,d2, L2) ¼ 108 M1. This is ;20-fold
too high relative to the measured value. It is possible that the
orientations of the SH3 and SH2 domains are not totally
random, as we have modeled, upon binding the bivalent
ligand. Orientational correlation will reduce p1(d1;L1,d2, L2)
and hence the predicted Ke value.
Proﬁt et al. (31,32) connected an SH2-targeting peptide
(Yp)EEIE with a kinase active-site directed inhibitor EE-
LL(F5Phe) by a tether consisting of g-aminobutyric acid
(GABA) residues. The ligands separately have binding
constants Kea0¼ 106 and 1.73 103 M1 for the Src SH2 and
kinase domains. The bivalent inhibitor with the highest
afﬁnity, 2.1 3 105 M1, has F5Phe and Yp linked by three
GABA residues. In an active conformation of Src kinase in
which the SH2 domain is dislocated from the kinase domain
(PDB entry No. 1y57) (6), the SH2 binding site and the
kinase active site are ;60 A˚ away (Fig. 4 b). The two
FIGURE 4 Complexes of multidomain pro-
teins with bivalent ligands. Protein domains are
shown as brown ribbon, individual ligands as
blue or purple ball-and-stick, and linkers be-
tween protein domains and between individual
ligands as black ball-and-stick. (a) Abl SH(32)
bound with linked 3BP-2 and 2BP-1 (PDB No.
2abl). PDB Nos. 1abo SH3 and 1bmb SH2 are
shown as cyan and yellow traces, respectively.
(b) Src kinase bound with linked (Yp)EEIE and
EELL(F5Phe) (PDB No. 1y57). The SH3 do-
main (gold ribbon) is bound to the PRP in
the SH2-kinase linker. PDB No. 1shd SH2 is
shown as yellow trace. Also shown in cyan is
Src kinase in an inactivated state (PDB No.
2src), with SH3 and SH2 as ribbon and kinase
domain as trace. Note the intramolecularly
bound Y527p . (c) Grb2 with linked dimer of
VPPPVPPRRR (PDB No. 1gri). PDB Nos.
3gbq nSH3 and 1sem cSH3 are shown as cyan
and yellow traces, respectively.
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domains must rearrange signiﬁcantly to bring the two
binding sites much closer to accommodate the bivalent
ligand.
To apply Eq. 17b to predict Ke, we take the linker between
the SH2 and kinase domains to be between residues P246 and
W260 (residue numbering according to PDB entry No. 1y57
(6) (Fig. 4 b)). The structure of the complex between the SH2
domain and (Yp)EEIE has been determined (PDB entry No.
1shd) (48). The distance between P246 and Yp in this
complex is d1 ¼ 22.8 A˚. No structure for EELL(F5Phe)
bound to the kinase domain can be found. We therefore take
the inhibitor found in 1y57 as a model of EELL(F5Phe) for
the purpose of calculating the distance d2 and the orientation
of the bound ligand. Speciﬁcally, d2 is measured between
P246 and atom C8 of the inhibitor in 1y57 and found to be
24.8 A˚; the vector from atom C8 to atom C9 of the inhibitor
is used to constrain the direction of the linker. With linker
lengths of L1 ¼ 14 and L2 ¼ 4, we ﬁnd p1(d1;L1,d2, L2) ¼
2.7 mM. From this we predict Ke ¼ Ke10Ke20p1(d1;L1,d2,
L2) ¼ 4.6 3 106 M1. This again is ;20-fold too high
relative to the measured value.
Vidal et al. (35) constructed a bivalent ligand for the two
SH3 domains of Grb2 by linking the C-terminals of two
copies of V1PPPVPPRRR10. Individually the PRP has bind-
ing constants Kea0 ¼ 3.8 3 105 and 2.5 3 104 M1 for the
N- and C-terminal SH3 domains (nSH3 and cSH3) of Grb2.
Upon linking two copies of the PRP by a single lysine the
bivalent ligand has a binding constant of 2.5 3 107 M1. In
the crystal structure of unbound Grb2 (PDB entry No. 1gri)
(49), the two PRP binding sites are .25 A˚ apart (Fig. 4 c),
and therefore cannot be spanned by a single-residue linker, in
contrast to observations of Vidal et al. (35) and Yuzawa et al.
(34). The latter authors also found experimental evidence
indicating that, in solution, the two SH3 domains of Grb2
move freely relative to each other and the whole protein is
less compact than the crystal structure.
The effective concentration for bivalent binding to Grb2
involves three ﬂexible linkers: the ﬁrst between nSH3 and
the SH2 domain, the second between the SH2 domain and
cSH3, and the third between the two PRP ligands (Fig. 4 c).
We take the ﬁrst linker to be between residues I53 and P59,
and the second linker to be between I151 and T159 (residue
numbering according to 1gri). The corresponding linker
lengths are L1 ¼ 6 and L2 ¼ 8, and the distance between the
linker attachment points (residues P59 and I151) in the SH2
domain is found to d2 ¼ 7.0 A˚ in 1gri. The distance d1 in
nSH3 between residue I53 and R10 of V1PPPVPPRRR10 is
measured from PDB entry No. 3gbq, which is the complex
between nSH3 and the PRP ligand. The result is d1¼ 19.2 A˚.
The distance d3 in cSH3 is measured on the complex of the
PRP ligand and the Caenorhabditis elegans homolog of
nSH3 (PDB entry No. 1sem) (50). As R9 and R10 of the
ligand are not visible in 1sem, d3 is measured between the
counterpart of Grb2 T159 and R8 of the ligand. This gives
d3¼ 24.5 A˚. The last two residues of the ligand is then treated
as part of the third ﬂexible linker, leading to L3 ¼ 4. With
these speciﬁcations, the effective concentration is found to
be 8 mM. The binding constant of the bivalent ligand is then
predicted to be 7.6 3 107 M1, which is comparable to the
experimental result of 2.5 3 107 M1. This calculation is
further supported by the experimental result of Vidal et al.
(35) for another bivalent ligand, constructed from a peptoid
analog of V1PPPVPPRRR10. For this ligand, the predicted
binding constant is 4.43 109 M1, which is the nearly same
as the experimental result of 5 3 109 M1.
Effects of linker length
In addition to the intramolecular binding between the SH3
domain and the PRP within the SH2-kinase linker, the Src
family kinases utilize a second mechanism for suppression of
kinase activity: binding of a phosphorylated tyrosine on the
C-terminal tail to the SH2 domain. Cobb et al. (51) found
that the linker length between the kinase domain and the in-
tramolecular ligand, Y527p , has signiﬁcant effect on the kinase
activity. Both deletion and insertion of two or four residues
resulted in kinase activation. If we take D518 and Y527p in the
inactivated form of Src kinase (PDB entry No. 2src) (5) as
the two attachment points of the linker, then the end-to-end
distance is d ¼ 15.9 A˚ and the native linker length is L ¼ 9.
Fig. 5 a shows that the effective concentration p(d) is max-
imal at the native linker length. Decrease or increase in linker
length through deletion or insertion leads to a lower effective
FIGURE 5 Effects of linker length on effective
concentration. (a) Decrease of p(d) with insertion
or deletion in the linker for intramolecular Y527p
binding to the Src kinase domain. (b) Variation of
the binding afﬁnity of PEG-linked cGMP dimer to
olfactory cyclic-nucleotide-gated channel. PEG
was modeled as a wormlike chain with persistence
length of 3.5 A˚ (66,67) and contour length given by
the number of monomer units (21.5 per 1000 mo-
lecular weight (68)) times a unit length of 2.8 A˚ (66).
Inter- and Intramolecular Binding 3177
Biophysical Journal 91(9) 3170–3181
concentration and thus a lower bound fraction. As a result the
kinase activity would be increased.
Kramer andKarpen (52) developed highly potent polymer-
linked ligand dimers for activating cyclic-nucleotide-gated
channels and cyclic GMP-dependent protein kinase. They
found that each target protein, with a given distance between
the two binding sites for a bivalent ligand, has an optimal
linker length. As illustrated in Fig. 5 b for the binding of
PEG-linked cGMP dimer to olfactory cyclic-nucleotide-
gated channel, the broad distribution of the binding constant
with polymer length is consistent with the effect of linker
length on the effective concentration. The structure of the
channel is not known. Best ﬁt to the experimental data for
binding gives a distance of 30 A˚ between the two binding
sites.
DISCUSSION
We have applied a quantitative relation between intermo-
lecular and intramolecular binding to predict the intramo-
lecular binding constant, the effect of an internal PRP ligand
on the folding stability of an SH3 domain, and the enhanced
afﬁnity from covalently linking two ligands for separate
binding sites. Despite the simplicity of the theoretical model,
the predictions generally agree reasonably well with exper-
imental results. These applications lead to several general
conclusions, which we now outline.
For an SH3 domain that uses intramolecular PRP binding
as a mechanism for regulation, the intramolecular binding
constant Ki should probably be ;1; values too high or too
low would mean that the regulatory switch is on or off all the
time. The applications presented here show that the effective
concentration p(d) is in the mM range. This requires that the
intermolecular binding constant of the internal ligand is of
the order of 103 M1. The requirement for such a low afﬁnity
explains why internal PRP ligands often have sequences that
deviate signiﬁcantly from ideal high-afﬁnity sequences, a
situation that has been termed ‘‘self-restraint’’ (19). This
observation also applies to intramolecular binding of Y527p to
the SH2 domain of Src Kinase; the afﬁnity of the native Y527p
sequence has been found to be 10,000-fold lower than that of
an ideal SH2 ligand (53). Other examples of intramolecular
binding in regulation include binding of the myristoylated
N-terminal of Abl kinase to its kinase domain (8,54), binding
of the receiver and effector domains of response regulator
NarL (55), and binding of the pocket and C-terminal domains
of the retinoblastoma protein (56).
Addition of ligands that favor the folded state over the
unfolded state is a very common strategy for increasing
protein stability. For an SH3 domain, covalently linking a
PRP with a bimolecular binding constant of ;106 M1 is
predicted to increase the folding stability by 15–20 kcal/mol.
As the stability of SH3 domains is often relatively low, one
wonders whether intramolecular PRP binding provides an in
vivo mechanism for stabilization. The same mechanism can
apply to the stabilization of other types of protein domains
that recognize different peptide motifs.
Covalent linking of two low-afﬁnity ligands may result in
a high-afﬁnity bivalent ligand. It has sometimes been sug-
gested that the afﬁnity Ke of the bivalent ligand is expected to
be the product of the afﬁnities Ke10 and Ke20 of the separate
ligands (29,57). Such a product will have units M2, inap-
propriate for a bimolecular binding constant Ke. The correct
formulation through Eqs. 16b and 17b predicts Ke as the
product of Ke10Ke20 and the effective concentration. The ef-
fective concentration depends on the distance between the
two binding sites and the linker length. As seen for the
binding of PEG-linked cGMP dimer to olfactory cyclic-
nucleotide-gated channel, for a given distance between the
binding sites, the linker length can be optimized. The ef-
fective concentration is in the mM range, thus as long as one
ligand has an afﬁnity greater than 103 M1, linking it to
another ligand will enhance the afﬁnity of the latter. For ex-
ample, for two ligands with afﬁnities of 105 and 106 M1, if
linking them has an effective concentration of 1 mM for the
two binding sites, the expected afﬁnity for the bivalent ligand
is 108 M1, which is 100- to 1000-fold higher than the af-
ﬁnities of the individual ligands.
The mM range of the effective concentration makes it easy
to achieve afﬁnity enhancement through covalent linking.
Proteins like Src family kinases and Grb2may actually utilize
the separate binding sites on SH3 and SH2 domains for high-
afﬁnity bivalent binding. Flexible linkers between the do-
mains allow the proteins to adapt to different targets. Afﬁnity
enhancement of bivalent binding has been observed in many
other designed and natural systems (56–65).
Effect of competitor on dissociation kinetics of
bivalent ligand
It is of interest to ask, in enhancing binding afﬁnity, whether
covalent linking of two separate ligands exerts its inﬂuence
through the association rate or the dissociation rate. A
previous kinetic analysis showed that the afﬁnity enhance-
ment is mainly manifested through decrease of the dissoci-
ation rate (11). This theoretical result is supported by
experimental observations of Kramer and Karpen (52) and
Walker et al. (61).
For a protein that is bound to a monovalent ligand, when a
competitor for the ligand is introduced, the rate of exchang-
ing to the competitor is the same as the dissociation rate of
the original ligand. If a bivalent ligand behaves the same
way, the exchange rate will be exceedingly small, given the
effect of covalent linking on the dissociation rate of the
bivalent ligand. However, both Kramer and Karpen (52) and
Rao et al. (60) observed fast exchange in the presence of
excess competitor.
The exchange between a bivalent ligand and a monovalent
competitor is illustrated in Fig. 6. With the elementary rate
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constants shown, it can be shown that the overall exchange
rate constant is
kex ¼ k1fk21 k1 ½C=ð11 k=k2Þg




where [C] is the concentration of the competitor. As [C]/
N, we have kex/ k1–, the dissociation rate from one of the
two binding sites, which is unaffected by covalent linking.
Kramer and Karpen (52) studied the dissociation kinetics of a
PEG-linked cGMP dimer from olfactory cyclic-nucleotide-
gated channel in the presence of cGMP. The dependence of
the dissociation rate on cGMP concentration appears to be in
qualitative agreement with Eq. 18.
Further reﬁnement of theoretical model
The model for linkers used here considers only statistical
distributions of the end-to-end vector. Effects such as
excluded-volume and other types of interactions between
linkers and protein domains and conformational preferences
of speciﬁc sequences may affect the effective concentration.
Such detailed effects can be captured by molecular dynamics
or Monte Carlo simulations. Given the encouraging results
presented here, such further reﬁnements seem well justiﬁed
and will be pursued in the future.
In summary, based on a quantitative relation between inter-
molecular and intramolecular binding, we have calculated
the intramolecular binding constant of the Itk SH3 domain
with an internal PRP, the stabilization of a circular permutant
of the a-spectrin SH3 domain by intramolecular binding of a
designed PRP, and the afﬁnity enhancement of a bivalent
ligand for the two SH3 domains of Grb2. These and other
examples suggest that ﬂexible linkers and sequence motifs
tethered to them, like folded protein domains, are also sub-
ject to tight control during evolution.
This work was supported in part by grant No. GM58187 from the National
Institutes of Health.
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